© 2002 Elsevier
Integrin activation unbends the molecule either by ligand binding or by effects on the cytoplasmic domains which straightens and separates the legs of the molecule. This exposes activation epitopes (red stars) and enables internalization of the signal. Two models for the proposed straightening are shown in B. The switchblade or flick-knife model and the angle-poise model differ in the way in which the C-termini of the legs relate to the transmembrane segments. (From R.O. Hynes,
Integrins serve as the cell's conduit to the outside world, sensing the external environment and passing on instructions: differentiate or not, adhere or move on, live or die. Their roles in controlling cell behavior, coupled with their cell-surface location, have made them highly attractive drug targets. But while researchers have made significant progress tracing integrin-related cell-signaling pathways, critical gaps remain.
In February, Elan and Biogen Idec...
POWER IN PAIRS
Integrins are the major adhesion receptors in cells, linking the extracellular matrix with internal cytoskeletal elements and signaling pathways. "Integrins are critical to how cells are instructed to move and differentiate at the right time and place," says Deepak Srivastava, University of California, San Francisco, who studies cardiovascular development. Thus they are key players in such processes as organogenesis and vascularization.
Each integrin contains an α and a β subunit. The genome contains on the order of 20 αs and 10 βs, leading to a large potential number of combinations. But not all are made. Some α and β subunits are "monogamous," preferring a single partner, says Hynes, while others are relatively promiscuous and form part of several different integrins.
The difficulty in linking integrins to specific processes is partially due to the sheer complexity of their expression. Cells usually express more than one integrin, in complex patterns that can change with time and environment and overlap between cell types, explains Hynes. Moreover, their key developmental role means that genetic knockouts are often embryonic lethal, precluding detailed studies of mutant animals.
In cancer, integrins are involved in loss of anchorage-dependent growth, tumor angiogenesis, and tumor-cell migration during tissue invasion and metastasis. "The rough rule is that stable adhesion is turned down and migratory adhesion is turned up in cancer cells," says Schwartz.
Cancer researchers have focused on the potential antiangiogenic properties of integrin inhibitors. Work by David Cheresh of The Scripps Research Institute in La Jolla, Calif., and others has shown that integrin αvβ3 inhibitors suppress tumor growth and disrupt angiogenesis in mice. Vitaxin, an antibody against αvβ3, is the "first anticancer integrin antagonist that shows efficacy," notes Cheresh, referring to recent successful trials in late-stage melanoma patients.
© 2002 Elsevier
In mammals, 8 β integrin subunits can assort with 18 a subunits to form 24 distinct integrins. These can be grouped based on evolutionary relationships, ligand specificity, and in the case of β2 and β7 integrins, restriction to the white blood cells. Green subunits are restricted to the chordates while orange subunits including receptors for Laminin and the RGD peptide sequence have orthologs in all metazoans. An asterisk denotes integrins that are alternatively spliced.
But αvβ3 presents a major discrepancy. Genetic knockout of β3, which would prevent αvβ3 formation, promotes tumor growth and angiogenesis in mice. Hynes favors another integrin, α5β1, as far more important in both tumors and normal development. Inhibitor and knockout results with α5β1 are in agreement, he says, showing that it is "clearly essential everywhere for blood vessel growth."
Hynes suggests that Vitaxin may instead inhibit αvβ3 expressed by the tumor cells themselves. Melanoma cells overexpress αvβ3 on occasion, and overexpression correlates with tumor invasiveness. "It's still unclear which integrins are most important for angiogenesis," he says. Underscoring his point, Judith Varner at the University of California, San Diego, recently revealed a previously unsuspected role in angiogenesis for yet another integrin, α4β1.1
Suiting Up Integrins for Tissue Engineering
Integrins are where "morphogenesis meets genetics," says Martin Schwartz of the University of Virginia. They instruct cells when and how to differentiate. They maintain cell junctions and allow tissues to mature. Tissue engineers would like to give similar instructions to stem cells, so they can repair defective hearts, missing bones, and other ailing body parts. These similarities have David Cheresh, of The Scripps Research Institute in La Jolla, Calif., predicting that "in the next 3 to 5 years, integrins will play a major role in the work of stem cell biologists."
Deepak Srivastava at the University of California, San Francisco, is studying how integrin-mediated signaling can be manipulated to promote heart repair. He has focused on thymosin β4, one of many proteins found with integrins in the large macromolecular complexes, just inside the cytoplasm, known as focal adhesions. "The focal adhesion is where the cell gets closest to the underlying substrate," says Jun-Lin Guan, who studies these complexes at Cornell University. "Receptors, cytoskeletal elements, and the ends of actin filaments are concentrated in this area."
When an integrin receives a signal on the cell surface, it stimulates integrin-linked kinase, or ILK, another focal-adhesion component, to phosphorylate other proteins, initiating a signaling cascade. Thymosin β4 strengthens the integrin-ILK interaction, thus "tuning up" signaling. Srivastava found that this improved signaling enhances cardiomyocyte migration and survival, repairing tissue in a mouse model of heart attack.1 Srivastava is seeking US Food and Drug Administration approval for clinical trials of thymosin β4.
Andres Garcia at the Georgia Institute of Technology is applying knowledge of integrins and the extracellular matrix to generate biomaterials that interact better with cells. For example, he plans to enhance integration of hip and knee implants by coating them with integrin-interacting materials promoting bone growth. At the same time, he plans to inhibit integrins involved in immune responses.
"The problem is really at the interface," he says. "The body reacts to foreign materials by trying to encapsulate them." Special coatings could promote interactions with desired cells, while discouraging encapsulation. He is testing coatings made of short synthetic peptides or protein fragments derived from extracellular matrix proteins that target known integrins.
"The biggest challenge is to target specific cells since different cells can have the same integrins," he says. Right now, he is focusing on how best to immobilize the coatings on the devices, but he plans to proceed to in vitro and in vivo models, and to be testing these devices in humans within 5 to 10 years. "It's a promising strategy," he says.
Such difficulties are not limited to angiogenesis. Jordan Kreidberg of Harvard Medical School is studying integrins in kidney organogenesis. He says that knockout of the four major integrins expressed in the kidney has led to "no great insight yet." Effects range from none, to some tubule disorganization, to the complete absence of kidneys. Researchers have yet to correlate these defects with specific integrins in specific cell types.
Kreidberg points out that "it's difficult to make links between the huge amount of in vitro data [on integrins] and their roles in development." In particular, there are problems going from two-dimensional tissue cultures to whole organs and embryos. "It's very difficult to measure signaling in a developing embryo. There's no huge burst of something happening like in tissue culture," he says.
Moreover, he suggests that tissue-culture studies may actually obscure understanding of integrin function. Cheresh and others agree that there are differences. Dynamic cell-cell interactions are absent in culture, says Cheresh, and the extracellular matrix is much less complex. "We cannot make conclusions from pure in vitro response," he notes. Of course, whole-organ and animal studies can't approach many questions yet. "We need both ways of looking at it," Hynes points out.
Complicating matters further, integrins exist in multiple activity states. "There is an activated form that binds ligands with high affinity, and a resting state that binds with low affinity," says Mark Ginsberg, who works on integrin structure at UC, San Diego. According to Hynes, "You must know if the integrin is activated" to interpret its role in a given cell. New reagents, such as monoclonal antibodies, could distinguish active from resting integrins, he says. He also envisions mice expressing tagged integrins that fluoresce only when activated, allowing in vivo measurement of activation states.
Despite these difficulties, integrin inhibitors are currently in clinical trials for cancer, including Vitaxin, and Celengitide for glioblastoma. Two others, Integrilin and ReoPro, have been approved as blood thinners in cardiovascular disease.
Cheresh says he's optimistic. "I think we will ultimately see several integrin antagonists... used as drugs for various indications." Tysabri is still having difficulties, even after favorable safety reviews announced last month. Cheresh and others speculate that Tysabri had a synergistic effect with immunosuppressive drugs that the patients were taking leading to the opportunistic infection that caused PML. "This agent does have a positive impact on MS," Cheresh says, and such a drug is sorely needed.